RSS   Newsletter   Contact   Advertise with us

Valeant to cut all ties with Philidor as soon as possible

Staff writer ▼ | October 30, 2015
Valeant Pharmaceuticals said it is severing all ties with Philidor Rx Services and that Philidor has informed Valeant that it will shut down operations as soon as possible.
Allegations   Philidor Rx Services is under microscope
In the Q3 2015, Philidor represented 6.8% of total Valeant revenue.

"The newest allegations about activities at Philidor raise additional questions about the company's business practices," said J. Michael Pearson, Valeant's chairman and chief executive officer.

"We have lost confidence in Philidor's ability to continue to operate in a manner that is acceptable to Valeant and the patients and doctors we serve."

"We understand that patients, doctors and business partners have been disturbed by the reports of improper behavior at Philidor, just as we have been," Pearson said.

"We know the allegations have also led them to question Valeant and our integrity, and for that I take complete responsibility. Operating honestly and ethically is our first priority, and you have my absolute commitment that we will make it right."

Valeant intends to develop a plan to ensure patients' access to drugs is minimally disrupted. Valeant has informed Philidor that to the extent that managed care plans will no longer reimburse prescriptions in process, Valeant will fill them at the company's expense.

"We are committed to doing everything we can to provide important medicines to the patients and doctors who depend on them, and will continue to explore relationships with the full range of pharmacies to ensure patients have access to the drugs they need," Pearson said.

In the Q3 2015, Philidor represented 6.8% of total Valeant revenue.